CCL1 and Alzheimer disease: In the CC motif, data from two cohorts of AD and MCI evaluating the chemokine CCL1 in plasma or serum, which included 120 AD patients and 95 MCI patients, revealed a substantial effect size (RoM, 1.37, 95% CI, 1.17–1.59, corrected p < 0.001; I2 = 0%; Table 2 and Figure S14 in Supplementary file).